Drug repurposing is a strategy that identifies new uses for already approved or investigational medicines outside their original indication. This approach can accelerate access to treatments, lower development costs, and reduce the risk of failure — offering particular promise for rare cancers such as sarcomas.

The article explores how repurposing could address unmet medical needs in sarcoma care, especially where commercial interest is limited. It also highlights the ongoing review of the EU Pharmaceutical Regulation and proposed Article 48, which could empower not-for-profit organizations and patient groups to take an active role in generating evidence for new therapeutic indications.

The Belgian-based AntiCancer Fund (ACF), together with SPAGN and the Fondazione Paola Gonzato-Rete Sarcoma, is leading efforts to advocate for these crucial regulatory changes — paving the way for greater innovation and improved patient access to new treatment options.